SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

BBIO

BridgeBio Pharma, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a routine conference presentation announcement with no new data disclosed. Monitor the actual presentation on May 12 for any material efficacy or safety updates that could move the stock. No immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$68.78
T+0 close · May 5, 2026 · via day close
Latest settled
+19.42%
T+60 · $82.14
Vs SPY
+16.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $68.78entry
  2. T+1 · 7mo ago −1.00%α −2.39% · $68.09
  3. T+5 · 6mo ago −4.11%α −6.10% · $65.95
  4. T+20 · 6mo ago −7.12%α −12.08% · $63.88
  5. T+60 · 4mo ago +19.42%α +16.68% · $82.14

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio Pharma announced it will present additional Phase 3 data for encaleret in ADH1 at the 2026 European Congress of Endocrinology, including an oral presentation of primary results. This is a routine data disclosure event with no new regulatory or financial catalysts, the data was already known from the Phase 3 trial.

Key Facts

  • BridgeBio will present primary Phase 3 CALIBRATE trial results for encaleret in ADH1 at ECE 2026 on May 12
  • Additional oral presentation on genetic testing of hypoparathyroidism patients
  • One poster and one ePoster on ADH1 quality of life and epidemiology
  • No new efficacy/safety data disclosed beyond the presentation schedule
  • No regulatory submission, approval, or financial guidance provided

Financial Impact

No financial impact, this is a data presentation announcement with no new material information

Risk Factors

  • No new data disclosed, market may have already priced in Phase 3 results
  • ADH1 is a small patient population, limiting commercial upside even if positive

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
97% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287541

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (14h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026